## **Special Issue**

# State-of-the-Art Dermatology in Spain

#### Message from the Guest Editors

This Special Issue entitled "State-of-the-Art Dermatology in Spain" aims to highlight the latest advances, challenges, and innovations in dermatological research and clinical practice in Spain. This Special Issue will feature original research and comprehensive reviews on emerging therapies, diagnostic techniques, and the evolving landscape of dermatological diseases, with a particular focus on translational medicine and personalized treatment approaches.

#### **Guest Editors**

Dr. Francisco José Navarro-Triviño

Contact Eczema and Immunoallergic Diseases, Dermatology Department, Hospital Universitario San Cecilio, Avda. del Conocimiento s/n, 18016 Granada, Spain

Dr. Ricardo Ruiz-Villaverde

Dermatology Department, Hospital Universitario San Cecilio, Instituto Biosanitario de Granada, Ibs, 18016 Granada, Spain

#### Deadline for manuscript submissions

closed (30 September 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/231552

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





### **About the Journal**

#### Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

#### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).